Compare MFA & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | PHAR |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.0M | 1.0B |
| IPO Year | 1998 | 2020 |
| Metric | MFA | PHAR |
|---|---|---|
| Price | $8.93 | $11.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $11.05 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 1.4M | 21.2K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 14.16% | N/A |
| EPS Growth | ★ 58.54 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | $10.02 | $2.51 |
| P/E Ratio | ★ $38.74 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.80 | $9.62 |
| 52 Week High | $10.57 | $21.34 |
| Indicator | MFA | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 46.47 |
| Support Level | $8.94 | $9.62 |
| Resistance Level | $9.38 | $13.51 |
| Average True Range (ATR) | 0.15 | 0.57 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 25.56 | 40.73 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets; and Lima One.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.